Aurionpro Solutions Limited 600-780
Expected level 1000
Support 427
Expected level 1000
Support 427
๐ฅ12
Laxmi Organic Industries Limited company details report
Laxmi Organic Industries Limited, incorporated in 1989 is a leading manufacturer of Acetyl Intermediates and Specialty Intermediates with almost three decades of experience in large scale manufacturing of chemicals. It started manufacturing glacial acetic acid in 1992, and thereafter moved on to manufacturing of ethyl acetate in 1996. In Fiscal 2010, it commenced manufacturing of Specialty Intermediates by acquiring Clariantโs diketene business. The companyโs product portfolio is currently divided into three broad categories, namely the Acetyl Intermediates, Speciality Intermediates and Fluorospeciality Intermediates. a) The Acetyl Intermediates include ethyl acetate, acetaldehyde, fuel-grade ethanol and other proprietary solvents. The company is currently amongst the largest manufacturers of ethyl acetate in India with a market share of ~30% and is the only Indian company with on ground presence in Europe for over ten years now. The acetyl products have applications in diverse industries such as pharmaceutical formulations, agrochemicals, ink & paints, coatings, packaging, adhesives and fragrance & flavour. b) The Specialty Intermediates comprises of ketene & diketene derivatives including esters, acetic anhydride, amides, and arylides. The company is the manufacturer of diketene derivatives in India with a market share of ~50%. The specialty intermediates have applications in pharmaceuticals, agrochemicals, dyes & pigments, flavour & fragrance, paints & coatings, flame redundant, and electronics.
Laxmi Organic Industries Limited, incorporated in 1989 is a leading manufacturer of Acetyl Intermediates and Specialty Intermediates with almost three decades of experience in large scale manufacturing of chemicals. It started manufacturing glacial acetic acid in 1992, and thereafter moved on to manufacturing of ethyl acetate in 1996. In Fiscal 2010, it commenced manufacturing of Specialty Intermediates by acquiring Clariantโs diketene business. The companyโs product portfolio is currently divided into three broad categories, namely the Acetyl Intermediates, Speciality Intermediates and Fluorospeciality Intermediates. a) The Acetyl Intermediates include ethyl acetate, acetaldehyde, fuel-grade ethanol and other proprietary solvents. The company is currently amongst the largest manufacturers of ethyl acetate in India with a market share of ~30% and is the only Indian company with on ground presence in Europe for over ten years now. The acetyl products have applications in diverse industries such as pharmaceutical formulations, agrochemicals, ink & paints, coatings, packaging, adhesives and fragrance & flavour. b) The Specialty Intermediates comprises of ketene & diketene derivatives including esters, acetic anhydride, amides, and arylides. The company is the manufacturer of diketene derivatives in India with a market share of ~50%. The specialty intermediates have applications in pharmaceuticals, agrochemicals, dyes & pigments, flavour & fragrance, paints & coatings, flame redundant, and electronics.
๐ฅ8โค2
c) The Fluoro speciality Intermediates business vertical of Laxmi Organic Industries is a highly specialized segment with complex chemistry and limited competition. Leveraging the acquisition of Miteni SpAโs Fluoro Specialities and electrochemical fluorination assets, the company has gained access to world-class technology, infrastructure, and a diverse product portfolio with over 100 offerings. With a dedicated facility in Lote-Parshuram, Maharashtra, the company is strategically positioned to establish a strong foothold in the Fluoro speciality Intermediates market. Fluoro speciality intermediates manufactured by the company will find applications in agrochemicals, cosmetics, flavours & fragrances, dyes & pigments, and in the medium to long term in electronics and automotive. The company has 50+ products and 620+ active customers. It has 4 manufacturing facilities (including two upcoming manufacturing facilities at Lote & Dahej). It expanded its scale of operations and global footprint with customers in over 52 countries including China, Netherlands, Russia, Singapore, United Arab Emirates, United Kingdom and United States of America.
โค4๐ซก1
#SALES #GROWTH
In FY24, the consolidated sales grew by 2.6% YoY to โน2,865 cr. The growth was led by 20% YoY volume growth while price realization remained under pressure. Segment wise, the essentials segment sales grew by ~3% YoY and specialties segment sales grew by ~15% YoY. Industry wise, the agrochemical segment continues to face intense competition, and pricing in the pharma segment remains under pressure. Geography wise, the growth was led by domestic market and North America market while Europe market witnessed weak demand for products. In 9M FY25, the sales grew by 9.6% YoY to โน2,276 cr led by 15% volume growth across both business segment. Segment wise, the essentials segment sales grew by 5% YoY and specialties segment sales grew by 20% YoY. The company witnessed volume growth mainly in Q2 FY25 of 14% YoY and in Q3 FY25 of 17% YoY. The revenue from domestic stood at 64% and exports at 36% in 9M FY25.
In FY24, the consolidated sales grew by 2.6% YoY to โน2,865 cr. The growth was led by 20% YoY volume growth while price realization remained under pressure. Segment wise, the essentials segment sales grew by ~3% YoY and specialties segment sales grew by ~15% YoY. Industry wise, the agrochemical segment continues to face intense competition, and pricing in the pharma segment remains under pressure. Geography wise, the growth was led by domestic market and North America market while Europe market witnessed weak demand for products. In 9M FY25, the sales grew by 9.6% YoY to โน2,276 cr led by 15% volume growth across both business segment. Segment wise, the essentials segment sales grew by 5% YoY and specialties segment sales grew by 20% YoY. The company witnessed volume growth mainly in Q2 FY25 of 14% YoY and in Q3 FY25 of 17% YoY. The revenue from domestic stood at 64% and exports at 36% in 9M FY25.
๐3โค2
#EBITDA #GROWTH
In FY24, the EBITDA grew by 7% YoY to โน256 cr because of decline in power & fuel cost and other expenses. The power & fuel cost declined by 9% YoY to โน229 cr (v/s โน252 cr in FY23) led by reduced coal prices. Segment wise, the specialties segment contributed 67% (FY23: 69%) to the EBITDA and essentials segment contributes about 33% (FY23: 31%) to the EBITDA. The companyโs loss of profit insurance claim for FY22 was settled in Q4 FY24 which added โน10 cr to the EBITDA. During the year, the company witnessed supply chain challenges due to the ongoing Red Sea crisis. The companyโs key raw material are acetic acid and ethyl alcohol. The price of acetic acid is linked to crude oil prices. Similarly, the price of local ethyl alcohol, derived from sugarcane molasses, is cyclical. In 9M FY25, the EBITDA grew by 31% YoY to โน221 cr led by strong growth in both the essentials and specialties segment.
In FY24, the EBITDA grew by 7% YoY to โน256 cr because of decline in power & fuel cost and other expenses. The power & fuel cost declined by 9% YoY to โน229 cr (v/s โน252 cr in FY23) led by reduced coal prices. Segment wise, the specialties segment contributed 67% (FY23: 69%) to the EBITDA and essentials segment contributes about 33% (FY23: 31%) to the EBITDA. The companyโs loss of profit insurance claim for FY22 was settled in Q4 FY24 which added โน10 cr to the EBITDA. During the year, the company witnessed supply chain challenges due to the ongoing Red Sea crisis. The companyโs key raw material are acetic acid and ethyl alcohol. The price of acetic acid is linked to crude oil prices. Similarly, the price of local ethyl alcohol, derived from sugarcane molasses, is cyclical. In 9M FY25, the EBITDA grew by 31% YoY to โน221 cr led by strong growth in both the essentials and specialties segment.
๐3โค2
#PAT #GROWTH
In FY24, the PAT declined by 3.3% YoY to โน121 cr. The decline in profit was on account of increase in depreciation cost and higher effective tax rate. The depreciation cost increased by 47% YoY to โน107 cr from โน72 cr in FY23 mainly due to capitalization of two projects in subsidiary at site-2 in Mahad that came on stream in Q3 FY24 and Q4 FY24. The effective tax rate in FY24 stood at 29.4% in FY24 (v/s 27.9% in FY23). In 9M FY25, the PAT increased by 20% YoY to โน92 cr. The depreciation cost increased by 11% YoY to โน85 cr in 9M FY25 due to capitalization of assets in Lote.
In FY24, the PAT declined by 3.3% YoY to โน121 cr. The decline in profit was on account of increase in depreciation cost and higher effective tax rate. The depreciation cost increased by 47% YoY to โน107 cr from โน72 cr in FY23 mainly due to capitalization of two projects in subsidiary at site-2 in Mahad that came on stream in Q3 FY24 and Q4 FY24. The effective tax rate in FY24 stood at 29.4% in FY24 (v/s 27.9% in FY23). In 9M FY25, the PAT increased by 20% YoY to โน92 cr. The depreciation cost increased by 11% YoY to โน85 cr in 9M FY25 due to capitalization of assets in Lote.
๐ฅ3
#EBITDA #MARGIN
In FY24, the EBITDA margin expanded by 36 bps YoY to 8.9% because of decline in power & fuel cost and other expenses. During the year, the gross margin of the company contracted by 71 bps YoY to 32.8% because of increase in raw material cost. The companyโs product ethyl acetate is a commodity product, and thus, vulnerable to volatility in raw material prices, which are governed by global supplydemand dynamics. The companyโs focus on high margin specialties products in the di-ketene derivatives and fluorochemicals segment will provide a stability to its earnings and improves its margins. In 9M FY25, the EBITDA margin expanded by 158 bps YoY to 9.7% mainly led by improvement in gross margin on account of operational efficiency. Segment wise, the essentials segment margin expanded by 88 bps YoY to 4.6% and specialties segment margin expanded by 169 bps YoY to 20.8%.
In FY24, the EBITDA margin expanded by 36 bps YoY to 8.9% because of decline in power & fuel cost and other expenses. During the year, the gross margin of the company contracted by 71 bps YoY to 32.8% because of increase in raw material cost. The companyโs product ethyl acetate is a commodity product, and thus, vulnerable to volatility in raw material prices, which are governed by global supplydemand dynamics. The companyโs focus on high margin specialties products in the di-ketene derivatives and fluorochemicals segment will provide a stability to its earnings and improves its margins. In 9M FY25, the EBITDA margin expanded by 158 bps YoY to 9.7% mainly led by improvement in gross margin on account of operational efficiency. Segment wise, the essentials segment margin expanded by 88 bps YoY to 4.6% and specialties segment margin expanded by 169 bps YoY to 20.8%.
๐4